Experimental Hematology
Volume 36, Issue 12 , Pages 1616-1624 , December 2008

Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients

  • Elaine M. Sloand

      Affiliations

    • National Heart Lung and Blood Institute, Hematology Branch, Bethesda, Md., USA
    • Corresponding Author InformationOffprint requests to: Elaine M. Sloand, M.D., National Heart Lung and Blood Institute, Hematology Branch (MS 2490), Bethesda, MD 20892-1260
    • ,
  • Loretta Pfannes

      Affiliations

    • National Heart Lung and Blood Institute, Hematology Branch, Bethesda, Md., USA
    • ,
  • Phillip Scheinberg

      Affiliations

    • National Heart Lung and Blood Institute, Hematology Branch, Bethesda, Md., USA
    • ,
  • Kenneth More

      Affiliations

    • Bethesda Naval Hospital, Bethesda, Md., USA
    • ,
  • Colin O. Wu

      Affiliations

    • Office of Biostatistics Research, Division of Prevention and Population Sciences, National Heart Lung and Blood Institute, Bethesda, Md., USA
    • ,
  • McDonald Horne

      Affiliations

    • Pathology Section, Office of Research Services, Office of the Director, National Institutes of Health, Bethesda, Md., USA
    • ,
  • Neal S. Young

      Affiliations

    • National Heart Lung and Blood Institute, Hematology Branch, Bethesda, Md., USA

Received 21 December 2007 ,Revised 12 June 2008 ,Accepted 17 June 2008.

References 

  1. Young NS. Paroxysmal nocturnal hemoglobinuria: current issues in pathophysiology and treatment. Curr Hematol Rep. 2005;4:103–109
  2. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699–3709
  3. Araten DJ, Luzzatto L. The mutation rate in PIG-A is normal in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2006;108:734–736
  4. Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193–207
  5. Babiker AA, Ronquist G, Nilsson UR, Nilsson B. Transfer of prostasomal CD59 to CD59-deficient red blood cells results in protection against complement-mediated hemolysis. Am J Reprod Immunol. 2002;47:183–192
  6. Brooimans RA, van Wieringen PAM, Van Es LA, Daha MR. Relative roles of decay-accelerating factor membrane cofactor protein and CD59 in the protection of human endothelial cells against complement-mediated lysis. Eur J Immunol. 1992;22:3135–3140
  7. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, et al. Human protectin (CD59), an 18,000-2000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 1990;71:1–9
  8. Sloand EM, Young NS. Thrombotic Complications in PNH. In:  Young NS,  Moss J editor. PNH and the GPI-Linked Proteins. San Diego, CA: Academic Press; 2000;p. 101–112
  9. Poskitt TR, Fortwengler HP, Lunskis BJ. Activation of the alternate complement pathway by autologous red cel stroma. J Exp Med. 1973;138:715–722
  10. Simak J, Holada K, Risitano AM, Zivny JH, Young NS, Vstal JG. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2004;125:804–813
  11. Hugel B, Socie G, Vu T, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood. 1999;93:3451–3456
  12. Grunewald M, Siegemund A, Grunewald A, et al. Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size. Blood Coagul Fibrinolysis. 2003;14:685–695
  13. Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells. 1997;15:398–408
  14. Ploug M, Eriksen J, Plesner T, Hansen NE, Dano K. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. Eur J Biochem. 1992;208:397–404
  15. Plesner T, Ploug M, Ellis V, et al. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood. 1994;83:808–815
  16. Moller LB. Structure and function of the urokinase receptor. Blood Coagul. Fibrinolysis. 1993;4:293–303
  17. Ronne E, Pappot H, Grondahl-Hansen J, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1995;89:576–581
  18. Ninomiya H, Hasegawa Y, Nagasawa T, Abe T. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity. Int J Hematol. 1997;65:285–291
  19. Jo M, Thomas KS, Wu L, Gonias SL. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J Biol Chem. 2003;278:46692–46698
  20. Bugge TH, Flick MJ, Danton MJ, et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A. 1996;93:5899–5904
  21. Higazi AA, Bdeir K, Hiss E, et al. Lysis of plasma clots by urokinase-soluble urokinase receptor complexes. Blood. 1998;92:2075–2083
  22. Liebman HA, Feinstein DI. Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor. Thromb Res. 2003;111:235–238
  23. Ellis V. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase. J Biol Chem. 1996;271:14779–14784
  24. Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem. 1999;264:2185–2188
  25. Maciejewski JP, Rivera C, Kook H, Dunn D, Young NS. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones. Br J Haematol. 2001;115:1015–1022
  26. Selleri C, Montuori N, Ricci P, et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood. 2005;105:2198–2205
  27. Horne MK, Goad JL, Merryman PK, Cullinane AM. Comparison of the effect of histidine-rich glycoprotein and 6-aminohexanoic acid on plasmin production and fibrinolysis in vitro. Thromb Res. 2000;99:179–186
  28. Sloand EM, Young NS, Sato T, Kumar P, Kim S, Weichold FF, et al. Secondary colony formation after long-term bone marrow culture using peripheral blood and bone marrow of HIV-infected patients. AIDS. 1997;11:1547–1553
  29. Sloand E, Young NS, Sato T, Kim S, Maciejewski JP. Inhibition of interleukin-1β-converting enzyme in human hematopoietic progenitor cells results in blockade of cytokine-mediated apoptosis and expansion of their proliferative potential. Exp Hematol. 1998;26:1093–1099
  30. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–1258
  31. Socié G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348:573–577
  32. Behrendt N, Dano K. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system. FEBS Lett. 1996;393:31–36
  33. Hoyer-Hansen G, Pessara U, Holm A, et al. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J. 2001;358:673–679
  34. Higazi AA, Upson RH, Cohen RL, et al. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. Blood. 1996;88:542–551
  35. Tefs K, Gueorguieva M, Klammt J, et al. Molecular and clinical spectrum of type I plasminogen deficiency: a series of 50 patients. Blood. 2006;108:3021–3026
  36. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102:3587–3591
  37. Devine DV. The effects of complement activation on platelets. Curr Top Microbiol Immunol. 1992;178:101–113
  38. Hillmen P, Muus P, Duhrsen U, et al. The terminal complement inhibitor eculizumab reduces thrombosis in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;108:23;Abstract

PII: S0301-472X(08)00417-7

doi: 10.1016/j.exphem.2008.06.016

Experimental Hematology
Volume 36, Issue 12 , Pages 1616-1624 , December 2008

Article Tools

* Image Usage & Resolution